Company intelligence / Profile preview
Riboway Therapeutics
Cambridge, Massachusetts, United Statesriboway.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Riboway Therapeutics has validated its AI-driven platform across five distinct targets. Its lead preclinical program addresses the root cause of a monogenic neurodegenerative disease. The company claims successful target validation and plans to reach clinical proof-of-concept within three years. No human data reported yet.
- Therapeutic areas
- Metabolic DisordersNeurology
- Modalities
- RNA therapySmall interfering RNA (siRNA)Antisense oligonucleotide (ASO)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Riboway Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Riboway Therapeutics.